A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients.

Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Vancomycin (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Savara Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Status changed from planning to not yet recruiting.
    • 07 Jan 2017 According to a Mast Therapeutics media release, this trial is expected to initiate in the third quarter of 2017.
    • 04 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top